TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05822479

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral ultrasound guided external oblique intercostal block (EOIB)
Description: Bilateral ultrasound-guided EOIB (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA~Multimodal analgesia :~Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, iv paracetamol 1 gr and iv morphine 0.05 mg/kg/ideal body weight (IBW) will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). Rescue analgesia, when necessary (if the resting NRS score is ≥4 despite PCA demand), 25 mg IV meperidine was administered in the recovery unit, and 50 mg intramuscular (IM) meperidine was administered in the ward.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Patients in this group will not be performed interfacial plane blocks.~Multimodal analgesia :~Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, iv paracetamol 1 gr and iv morphine 0.05 mg/kg/ideal body weight (IBW) will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). Rescue analgesia, when necessary (if the resting NRS score is ≥4 despite PCA demand), 25 mg IV meperidine was administered in the recovery unit, and 50 mg IM meperidine was administered in the ward.
Study: NCT05303038

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cryoablation Combined with Tirelizumab and Bevacizumab
Description: Cryoablation of 1-2 typical metastatic lesions will be performed on D1 under general anesthesia and ultrasound guidance for two cycles.~200mg Tirelizumab ( IV Q3W) + Bevacizumab 7.5mg/kg ( IV Q3W) will be administered at D14 after cryoablation.
Study: NCT04228549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyPADMGT
Description: Online tracking and feedback to help patients adopt healthy lifestyles
Study: NCT05113940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days
Study: NCT04808453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-300
Description: CPI-300 will be administered via intravenous infusion on Day 1 of a 14-Day cycle
Study: NCT05113940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; Q8H or Q12H over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; Q8H or Q12H over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; Q8H or Q12H over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; Q8H or Q12H over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; Q8H or Q12H over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; Q8H or Q12H over 14 days
Study: NCT06634459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Pessary
Description: Gellhorn pessary or ring with/without support without knob pessary
Study: NCT04961619

Intervention type: DRUG
Intervention: dabrafenib
Description: There is no treatment allocation. Patients administered dabrafenib by prescription that have started before inclusion of the patient into the study will be enrolled.

Intervention type: DRUG
Intervention: trametinib
Description: There is no treatment allocation. Patients administered trametinib by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT06634849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTT-4256
Description: Single oral intake of PTT-4256 followed by treatment-free period of 3 days to assess safety, PK and PD. After 72-hr post dose PK sample, first 21day cycle of once daily PTT-4256 will begin to assess DLTs. Cohort 1-3 will receive 10mg, 20mg \& 40mg.
Study: NCT05113940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; Q8H or Q12H over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; Q8H or Q12H over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; Q8H or Q12H over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; Q8H or Q12H over 14 days
Study: NCT04952857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol 6 lakh IU
Description: vitamin D levels and serum calcium will be assessed at day 3,7, 14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cholecalciferol 6 lakh IU
Description: vitamin D levels and serum calcium will be assessed at day 3,7, 14.
Study: NCT04228549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyPADMGT + Nudging
Description: Online tracking and feedback to help patients adopt healthy lifestyles plus nudging support to assist in making decisions
Study: NCT05488938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitative Intervention
Description: Each program will require the daily performance of different postures and therapeutic activities at the girls' educational facilities and homes, based on the availability of families, for 10 months. Specific strategies that will be implemented will include maintaining asymmetrical postures that oppose the scoliosis curve during activities and exercises in sitting, standing, and walking positions (according to each participant's functional abilities). These strategies refer to a hypercorrective postural positioning of scoliosis. In addition, activities involving weight bearing on the lower limbs, such as walking and standing for at least two hours a day, will be encouraged, and passive stretching and spinal mobilization exercises will be conducted.
Study: NCT05113940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; Q8H or Q12H over 14 days
Study: NCT05113940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; Q8H or Q12H over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07258669
Study: NCT06108284

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Arm (Biphasic cuirass ventilation)
Description: Patients in this arm will be placed on Biphasic cuirass ventilation
Study: NCT06430892

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Primary Percutaneous Coronary Intervention (PPCI)
Description: Patients presented with acute myocardial infarction undergoing primary percutaneous coronary intervention with stent deployment

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Primary Percutaneous Coronary Intervention (PPCI)
Description: Patients presented with acute myocardial infarction undergoing primary percutaneous coronary intervention with stent deployment
Study: NCT05443022

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: Participants will receive an application of low intensity light directly in the region of the three pairs of salivary glands. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Simulation of Photobiomodulation
Description: The placebo group will have a simulation of the application of the laser, following the same technique as the active group, but with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off.
Study: NCT05631132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BAL + PAP
Description: May noninvasive mechanical ventilation (NIV) and/or continuous positive airway pressure (CPAP) increase the bronchoalveolar lavage (BAL) salvage in patients with pulmonary diseases?

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BAL + PAP
Description: May noninvasive mechanical ventilation (NIV) and/or continuous positive airway pressure (CPAP) increase the bronchoalveolar lavage (BAL) salvage in patients with pulmonary diseases?
Study: NCT05405426

Intervention type: OTHER
Group type: OTHER
Intervention: Red blood cell transfusion
Description: The intervention is a strategy for when red blood cell transfusion will be administered (see description of Arms). However, volume of RBC transfused in the two arms is not specified by this study. Red blood cell transfusion strategy for ECMO weaning and decannulation is not specified by this study. Red blood cell transfusion after ECMO decannulation is not specified by this study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: The intervention is a strategy for when red blood cell transfusion will be administered (see description of Arms). However, volume of RBC transfused in the two arms is not specified by this study. Red blood cell transfusion strategy for ECMO weaning and decannulation is not specified by this study. Red blood cell transfusion after ECMO decannulation is not specified by this study.
Study: NCT05827666

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2% milk beverage
Description: Protein provided at 0.3 g/kg fat-free mass. All other conditions (almond, soy and rice milk alternative beverages) will be matched to the same energy content (i.e., isoenergetic). Macronutrient content of beverage (per 100 g): Calories: 52 kcal; Fat: 2.25 g; Carbohydrates: 4.8 g; Protein: 3.3 g.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2% milk beverage
Description: Protein provided at 0.3 g/kg fat-free mass. All other conditions (almond, soy and rice milk alternative beverages) will be matched to the same energy content (i.e., isoenergetic). Macronutrient content of beverage (per 100 g): Calories: 52 kcal; Fat: 2.25 g; Carbohydrates: 4.8 g; Protein: 3.3 g.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2% milk beverage
Description: Protein provided at 0.3 g/kg fat-free mass. All other conditions (almond, soy and rice milk alternative beverages) will be matched to the same energy content (i.e., isoenergetic). Macronutrient content of beverage (per 100 g): Calories: 52 kcal; Fat: 2.25 g; Carbohydrates: 4.8 g; Protein: 3.3 g.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Almond milk alternative beverage
Description: Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 24 kcal; Fat: 1.13 g; Carbohydrates: 3.1 g; Protein: 0.3 g.
Study: NCT06394973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T4090 0.2%
Description: 1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
Study: NCT06041750

Intervention type: PROCEDURE
Intervention: Elective surgical procedure under general anesthesia
Description: The incidence of postoperative pulmonary complications in OSAS patients undergoing elective surgery under general anesthesia will be determined.
Study: NCT06457126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training Technique
Description: Phase 1: Non-concurrent multiple baseline design A-B design where the ATT (B) is introduced sequentially across participants. ATT and baseline (A) will be alternated on a weekly basis.~Phase 2: Alternating treatment design where an active (B) and passive (C) version of the ATT are rapidly and frequently alternative within the same participant on a weekly basis (e.g., A-B-A-C-A or A-C-A-B-A).
Study: NCT06394973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T4090 0.3%
Description: 1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhopressa®
Description: 1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
Study: NCT06243796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flap fixation technique
Description: After complete the modified radical mastectomy procedure, the researcher will use absorbable sutures (vicryl), multiple alternating stitched 2.5 cm apart between the subcutaneous of the flap and underlying muscle
Study: NCT04988230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
Study: NCT06216340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henagliflozin
Description: 10mg of Henagliflozin and diet-exercise therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo and diet-exercise therapy
Study: NCT04988230

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Energy Restriction
Description: Participants will follow receive a diet of 1500-1800kcal/ d for men and 1200-1500kcal/d for women, without restriction on feeding time.
Study: NCT05819229

Intervention type: DRUG
Intervention: Oral antibiotic therapy
Description: Empirical choice: amoxicillin-clavulanic acid 50 mg/kg/day divided into three doses.~If the sensitivity pattern is available, another oral antibiotic, preferably smaller-spectrum, can be used instead.~Total duration of antibiotic therapy will be 10 days.
Study: NCT06263712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attempted Suicide Short Intervention Program (ASSIP)
Description: The Attempted Suicide Short Intervention Program (ASSIP) is a specific therapy for patients with a suicide attempt in their biography. The brief therapy ASSIP consists of three to four sessions of approximately 50 minutes each.~Session 1: A narrative interview is conducted, in which the patient is asked to tell her\*his personal story which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behavior is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care plus resource interview group (STAR)
Description: The standard of care plus resource interview group (STAR) will be offered a clinical interview, a risk assessment, and a non-specific resource focused intervention over three face-to-face sessions. In this resource focused intervention, the patient is asked to name her\*his resources, describe them, and give examples.
Study: NCT05670106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA-617
Description: Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive/best standard of care (BS/BSOC)
Description: Best supportive/best standard of care as defined by the local investigator
Study: NCT05088148

Intervention type: OTHER
Intervention: . Pesticide and Pharmaceutical analysis
Description: Pesticide and Pharmaceutical analysis will be done with LC-MS/MS device.

Intervention type: OTHER
Intervention: . Pesticide and Pharmaceutical analysis
Description: Pesticide and Pharmaceutical analysis will be done with LC-MS/MS device.
Study: NCT04996693

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Imaging on Scanner with Spectral Imaging Capabilities
Description: Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar in all three arms.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT Scan using an Energy-Integrating Detector CT (128 slice MDCT)
Description: Patients will undergo imaging on a modern 128-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT Scan using an Energy-Integrating Detector CT (20-slice MDCT)
Description: Patients will undergo imaging on a modern 20-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
Study: NCT05187169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VS-6766
Description: Dual RAF/MEK inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VS-6766
Description: Dual RAF/MEK inhibitor
Study: NCT04751643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3)
Description: Therapeutic plasma exchange (TPE) ; 3 sessions in 3 consecutive days (Day 1 to Day 3) in intensive care unit in addition to usual treatments.~Plasma removed is replaced by thawed fresh frozen plasma. Plasma blood volume exchanged : 1.2 Apheresis type: centrifugation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual treatments in intensive care unit according to the current state of knowledge
Description: Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual treatments in intensive care unit according to the current state of knowledge
Description: Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)
Study: NCT05827666

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Almond milk alternative beverage
Description: Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 24 kcal; Fat: 1.13 g; Carbohydrates: 3.1 g; Protein: 0.3 g.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Almond milk alternative beverage
Description: Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 24 kcal; Fat: 1.13 g; Carbohydrates: 3.1 g; Protein: 0.3 g.
Study: NCT05936086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Cytoxan 40mg/kg iv qd x 2days (day 1 and 2);

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: etoposide(VP16):150 mg/m2, twice a week, 1-2 weeks; 150mg/m2, once a week for the 3rd to 6th week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone: 10 mg/m2/day, week 1 to 2; 5 mg/m2/d for the 3rd to 4th week; 2.5 mg/m2/ day at week 5-6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone: 10 mg/m2/day, week 1 to 2; 5 mg/m2/d for the 3rd to 4th week; 2.5 mg/m2/ day at week 5-6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine (CSA)
Description: Cyclosporine (CSA) 100mg Bid, week 1 to 6 (dosed according to 2004 version).
Study: NCT05966818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin and Standard therapy (ACEI or ARB).
Description: Dapagliflozin (Diglifloz) 10 mg orally once daily for 24 weeks and the standard therapy (ACEI or ARB).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin and Standard therapy (ACEI or ARB).
Description: Dapagliflozin (Diglifloz) 10 mg orally once daily for 24 weeks and the standard therapy (ACEI or ARB).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy (ACEI or ARB).
Description: Standard Therapy which include either ACEI or ARB for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy (ACEI or ARB).
Description: Standard Therapy which include either ACEI or ARB for 24 weeks.
Study: NCT06033274

Intervention type: DEVICE
Intervention: Transcatheter Tricuspid Valve Replacement
Description: All patients undergoing Transcatheter Tricuspid Valve Replacement for native tricuspid valve disease
Study: NCT06310655

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton SBRT
Description: Patients will receive SBRT over 5 days, either every day or every other day, to a dose of 25-50 Gy.